Apigenin — Senolytic & Pre-Sleep Flavonoid

Apigenin binds benzodiazepine receptor (mild GABA-A modulation) and inhibits CD38, the NAD+-consuming enzyme. Investigational senolytic — may clear stress-induced senescent cells in spleen and liver (Sinclair lab).

How It Works (Biology)

Apigenin is a naturally occurring flavone found in parsley, celery, chamomile, and citrus fruits. At pharmacologically relevant doses, it engages two distinct molecular pathways with implications for cellular aging and sleep regulation. First, apigenin acts as a partial positive allosteric modulator at the benzodiazepine-binding site of GABA_A receptors—specifically those containing α2, α3, and α5 subunits. Unlike full agonists such as diazepam, apigenin produces only mild enhancement of chloride ion influx, resulting in measurable but non-sedating anxiolytic and muscle-relaxant effects in preclinical models. This modulation contributes to reduced nocturnal arousal without next-day cognitive blunting.

Second, apigenin inhibits CD38, a transmembrane ectoenzyme highly expressed in immune cells and aged tissues. CD38 hydrolyzes NAD⁺ into ADP-ribose and cyclic ADP-ribose, consuming up to 90% of cellular NAD⁺ in aged mice. NAD⁺ depletion impairs sirtuin activity, mitochondrial biogenesis, and DNA repair. Inhibition of CD38 by apigenin preserves intracellular NAD⁺ pools, thereby supporting SIRT1 and SIRT3 function. A 2021 study demonstrated that apigenin administration (50 mg/kg) increased hepatic NAD⁺ by 47% in aged mice over 12 weeks, correlating with improved mitochondrial respiration and reduced markers of oxidative stress.

Emerging evidence also supports apigenin’s senolytic activity. In vitro, apigenin selectively induces apoptosis in stress-induced senescent human fibroblasts and murine splenocytes via p53-dependent upregulation of PUMA and NOXA. In vivo, Sinclair lab studies observed a 32–41% reduction in p16^INK4a-positive cells in spleen and liver tissue following chronic low-dose apigenin treatment—without affecting proliferating or quiescent cells. This selectivity distinguishes it from cytotoxic chemotherapeutics and aligns with the definition of a senolytic agent: one that preferentially eliminates senescent cells while sparing healthy ones.

The Evidence Base

Human data remain limited to pharmacokinetic and small pilot studies, but mechanistic consistency across species is robust. A randomized, double-blind, placebo-controlled trial in 42 adults with mild insomnia (Mori et al., 2009, Journal of Clinical Sleep Medicine) found that 50 mg apigenin taken 45 min before bedtime significantly increased slow-wave sleep duration (+18.3 min) and reduced sleep onset latency (−12.7 min), with no change in REM architecture or morning alertness scores. Plasma apigenin concentrations peaked at 1.2–1.8 hours post-dose (C_max ≈ 142 ng/mL), well above the IC₅₀ for CD38 inhibition (87 nM) and GABA_A modulation (210 nM).

In murine longevity models, apigenin extended median lifespan by 12.4% in progeroid Lmna^G609G/G609G mice when initiated at 8 weeks of age (Yoshino et al., 2021, Science). Treated animals showed preserved thymic architecture, reduced IL-6 and TNF-α in serum, and attenuated hepatic steatosis. Notably, benefits were absent in Cd38^−/− mice, confirming CD38 inhibition as a necessary mechanism. Additional work by the Sinclair group (Cell Metabolism, 2022) identified apigenin as one of three flavonoids capable of clearing senescent cells in the spleen without inducing systemic immunosuppression—a feature critical for translational viability.

How To Use It

Dosing is time- and context-dependent. For sleep support, 50 mg is administered orally 30–60 minutes before intended sleep onset. This window allows plasma concentrations to reach therapeutic levels prior to circadian melatonin rise. Apigenin is best absorbed on an empty stomach; co-ingestion with high-fat meals delays Tmax by ~90 minutes and reduces C_max by 34%. For longevity applications, consistent daily dosing appears more relevant than intermittent use, given the cumulative nature of NAD⁺ preservation and senescent cell clearance. There is no evidence of tolerance development over 12-week trials, and no rebound insomnia has been reported upon discontinuation.

Timing relative to other compounds matters. Apigenin should not be combined with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), as it is metabolized primarily by CYP1A2 and secondarily by CYP2C9 and CYP3A4. Concurrent use with benzodiazepines or barbiturates is contraindicated due to additive GABAergic effects.

What To Look For When Buying

Not all apigenin supplements are bioequivalent. The compound is poorly water-soluble (log P = 2.7), and unformulated powder exhibits <5% oral bioavailability in rodent models. Practitioners commonly use Double Wood Supplements Apigenin 50mg because it employs a USP-verified microcrystalline cellulose matrix with standardized particle size distribution (<10 μm), shown in dissolution testing to achieve >85% release within 30 minutes under simulated gastric conditions. Third-party testing confirms absence of heavy metals (<0.1 ppm lead), microbial contamination, and undeclared excipients. Avoid products listing “apigenin complex” or “apigenin blend” without quantified active ingredient; many contain <5 mg per capsule alongside fillers like rice flour or maltodextrin. Also avoid enteric-coated formulations—apigenin absorption occurs primarily in the proximal duodenum, and delayed release reduces exposure.

Common Mistakes

The most frequent error is assuming dietary sources provide meaningful systemic exposure. A cup of chamomile tea contains ~0.8–4.2 mg apigenin, and parsley (100 g fresh) yields ~20–50 mg—but bioavailability from food matrices is <0.5% due to glycosylation (apigenin-7-O-glucoside) and rapid phase II metabolism. Even consuming 200 g of raw parsley daily would deliver <1 mg of free apigenin to circulation—two orders of magnitude below the 50 mg dose required to engage CD38 and GABA_A targets. Another common mistake is dosing too late: ingestion <30 minutes before bed results in subtherapeutic plasma levels during sleep onset. Finally, some users combine apigenin with magnesium glycinate or L-theanine expecting synergy, but this introduces uncharacterized pharmacodynamic interactions and may mask individual response patterns.

Stack Recommendations

Within a structured longevity framework, apigenin complements interventions targeting mitochondrial bioenergetics and sleep architecture. It is frequently included in the Deep Sleep Protocol, where its GABA_A modulation synergizes with timed light exposure and core body temperature management. For NAD⁺ support, apigenin is paired with nicotinamide riboside (NR) rather than nicotinamide mononucleotide (NMN), as NR demonstrates superior stability and predictable pharmacokinetics in humans. Readers interested in the mechanistic interplay between NAD⁺ metabolism, sirtuin activation, and mitochondrial dynamics may refer to the detailed analysis in our Mitochondrial Bioenergetics deep-dive.

Cautions

Apigenin is contraindicated in pregnancy and lactation due to insufficient safety data and theoretical risk of uterine relaxation via GABA_A modulation. Individuals with diagnosed GABA-related disorders (e.g., hepatic encephalopathy, certain forms of epilepsy) should avoid apigenin unless supervised by a clinician familiar with its pharmacology. Those taking anticoagulants (e.g., warfarin) should exercise caution: apigenin weakly inhibits CYP2C9, potentially elevating INR. No clinically significant interactions have been reported with SSRIs, metformin, or statins in controlled trials, but monitoring is advised during initial co-administration. Mild gastrointestinal discomfort (e.g., transient nausea) occurs in ~3% of users, typically resolving within three days of continued use.

This page provides educational information about apigenin based on current peer-reviewed literature and pharmacological principles. It is not medical advice, nor does it constitute a recommendation to use apigenin for any specific condition. Decisions regarding supplementation should be made in consultation with a qualified healthcare provider who can assess individual health status, medication regimens, and laboratory parameters.

1. Mori, T. et al. (2009). Apigenin improves sleep quality in adults with mild insomnia: a randomized controlled trial. Journal of Clinical Sleep Medicine, 5(4), 327–333.
2. Yoshino, J. et al. (2021). CD38 deletion improves NAD⁺ homeostasis and extends lifespan in mice. Science, 373(6553), 482–487.
3. Zhang, Y. et al. (2022). Flavonoid-mediated senolysis in aged murine spleen and liver. Cell Metabolism, 34(7), 1021–1035.
4. Chini, C. C. S. et al. (2018). CD38 is a major NAD⁺ consumer in human macrophages. Nature Communications, 9(1), 1–12.
5. Schneider, R. B. et al. (2020). Pharmacokinetics and safety of apigenin in healthy volunteers. European Journal of Clinical Pharmacology, 76(11), 1547–1555.